Research Article 
Influence of apolipoprotein E ε4 on rates of cognitive and functional decline in mild cognitive impairment
Danielle C. Whitehair, Abdullah Sherzai, Jennifer Emond, Rema Raman, Paul S. Aisen, Ronald C. Petersen and Adam S. Fleisher
Alzheimer`s & Dementia, 2010, 6(5), 412-419. DOI: 10.1016/j.jalz.2009.12.003
Abstract
Background: Apolipoprotein E ε4 (APOE ε4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE ε4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE ε4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). Methods: A total of 516 aMCI participants aged 55–90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE ε4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. Results: APOE ε4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE ε4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. Conclusions: These findings demonstrate that APOE ε4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE ε4 status needs to be accounted for in treatment trials of MCI.
ASCI-ID: 285-17
Similar Articles
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s disease
Alzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012
Leptin and dementia over 32 years–The Prospective Population Study of WomenAlzheimer`s & Dementia, 2012, 8(4), 272-277. DOI: 10.1016/j.jalz.2011.05.2411
Drug treatment of Alzheimer’s disease patients leads to expression changes in peripheral blood cellsAlzheimer`s & Dementia, 2010, 6(5), 386-393. DOI: 10.1016/j.jalz.2009.12.004
White matter is altered with parental family history of Alzheimer’s diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
Update on the Magnetic Resonance Imaging core of the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 212-220. DOI: 10.1016/j.jalz.2010.03.004
Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjectsAlzheimer`s & Dementia, 2010, 6(3), 230-238. DOI: 10.1016/j.jalz.2010.03.008
Clinical core of the Alzheimer’s disease neuroimaging initiative: Progress and plansAlzheimer`s & Dementia, 2010, 6(3), 239-246. DOI: 10.1016/j.jalz.2010.03.006
The informatics core of the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 247-256. DOI: 10.1016/j.jalz.2010.03.001
The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002
Temporal lobe functional activity and connectivity in young adult APOE ε4 carriersAlzheimer`s & Dementia, 2010, 6(4), 303-311. DOI: 10.1016/j.jalz.2009.07.003
The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plansAlzheimer`s & Dementia, 2010, 6(3), 265-273. DOI: 10.1016/j.jalz.2010.03.013
Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: The essential role of the Neuropathology CoreAlzheimer`s & Dementia, 2010, 6(3), 274-279. DOI: 10.1016/j.jalz.2010.03.012
Alzheimer’s Disease Neuroimaging Initiative in EuropeAlzheimer`s & Dementia, 2010, 6(3), 280-285. DOI: 10.1016/j.jalz.2010.03.005
The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardAlzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009
Japanese Alzheimer’s Disease Neuroimaging Initiative: Present status and futureAlzheimer`s & Dementia, 2010, 6(3), 297-299. DOI: 10.1016/j.jalz.2010.03.011
An examination of Alzheimer’s disease case definitions using Medicare claims and survey dataAlzheimer`s & Dementia, 2010, 6(4), 334-341. DOI: 10.1016/j.jalz.2009.09.001
Deliberative assessment of surrogate consent in dementia researchAlzheimer`s & Dementia, 2010, 6(4), 342-350. DOI: 10.1016/j.jalz.2009.06.001
Priorities for research consortia on Alzheimer's diseaseAlzheimer`s & Dementia, 2010, 6(4), 359-362. DOI: 10.1016/j.jalz.2010.05.2017
Improving Alzheimer‘s disease phase II clinical trialsAlzheimer`s & Dementia, 2013, 9(1), 39-49. DOI: 10.1016/j.jalz.2012.02.002
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012
Leptin and dementia over 32 years–The Prospective Population Study of WomenAlzheimer`s & Dementia, 2012, 8(4), 272-277. DOI: 10.1016/j.jalz.2011.05.2411